Therapeutic perspectives for adult soft tissue sarcoma-updates from the 2022 ASCO annual meeting.

At the recent 2022 American Society of Clinical Oncology (ASCO) annual meeting, the latest progress was presented in clinical trials of various therapeutic modalities for adult soft tissue sarcoma (STS), including chemotherapy, targeted ther-apy, anti-immune checkpoint immunotherapy, and multiple combination treatments (Table 1). Generally, the development of clinical treatments for STS is relatively slow, owing to the complex pathological subtypes of sarcoma and their heter-ogeneous biological behaviors. Here, we briefly summarize updates from this year's ASCO meeting and discuss the future therapeutic perspectives for unspecific STS.